ViewRay Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

ViewRay hat ein Gesamteigenkapital von $55.3M und eine Gesamtverschuldung von $77.8M, was einen Verschuldungsgrad von 140.7% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $233.2M bzw. $177.9M.

Wichtige Informationen

140.7%

Verhältnis von Schulden zu Eigenkapital

US$77.76m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$81.29m
Eigenkapital	US$55.26m
Gesamtverbindlichkeiten	US$177.90m
Gesamtvermögen	US$233.16m

Jüngste Berichte zur Finanzlage

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Dec 24

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: VRAY.QDie kurzfristigen Aktiva des Unternehmens ($193.6M) übersteigen seine kurzfristigen Passiva ($166.8M).

Langfristige Verbindlichkeiten: VRAY.QDie kurzfristigen Vermögenswerte des Unternehmens ($193.6M) übersteigen seine langfristigen Verbindlichkeiten ($11.1M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: VRAY.Q über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: VRAY.QDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 77.3% auf 140.7% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: VRAY.Q hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: VRAY.Q hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 2% pro Jahr abnimmt

ViewRay Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

Motion for Joint Administration Filed by ViewRay, Inc.

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) Shares

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?